ClinicalTrials.gg
Enrolling by invitationNCT05846854Updated May 6, 2023

Decreasing Hemorrhage Risk in Children With Alagille Syndrome

An interventional study of Assessment for bleeding disorder with tailored post-operative care in Alagille Syndrome, Pulmonary Artery Stenoses and Acquired Von Willebrand Disease, sponsored by Stanford University. Enrolling by invitation at 1 site in United States. Open to participants aged Up to 17 Years. Per ClinicalTrials.gov, last updated 2023-05-06.

Sponsored by Stanford University · Not applicable, Interventional, and Prevention

How we know

From the registry’s dates

  • Primary completion was expected by Nov 2024, 2 years ago, but the record still lists the study as enrolling by invitation.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
40
Allocation
Non-randomized
Ages
Up to 17 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 17 studies in Alagille Syndrome with a site in United States — 5 open to participants now, 6 under way, 1 of them phase 3. Alagille Syndrome · United States.

Started
2023
with 1 other
No phase
2 of 17
1 open now
Registered
14th of 17
by date
Lead sponsor
2 of 17
Stanford University

Among the 17 studies in Alagille Syndrome with a site in United States, this one is one of 2 that started in 2023, is one of 2 with no phase, and was the 14th registered.

Alagille Syndrome

31 studies on the registry are indexed under Alagille Syndrome; 11 are open to participants now.

Browse Alagille Syndrome studies →

Open to participants now

5 of the 17 studies in Alagille Syndrome with a site in United States are open now. Recruiting first, the newest first:

All 5 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 10 Alagille Syndrome studies recruiting now, 7 (70%) set no upper age limit and 3 (30%) stop at 75 or younger; 9 take children under 18; none take healthy volunteers.

This study: Up to 17 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 17 studies in Alagille Syndrome with a site in United States, or all of them as a file.
02

Study summary

The goal of this interventional study is to test a hemostasis screening protocol and cardiac peri-procedural and post-operative hemostasis pathway to improving bleeding complications and improve patient survival for children with Alagille syndrome and complex cardiac conditions. The main questions it aims to answer are:

  • Are children with Alagille syndrome with cardiac anomalies more likely to have acquired von Willebrand syndrome (a condition that causes increased bleeding)
  • Does implementation of a novel screening protocol to detect pre-operative bleeding conditions decrease intra-operative and/or post-operative bleeding complications and mortality risk?
  • Does implementation of a novel screening protocol to detect and treat bleeding conditions cause thrombotic complications?

Participants will undergo additional hematology and bleeding disorder screening prior to cardiac surgery. They will additionally undergo a detailed family screening for a history of bleeding by a genetic counselor.

Researchers will compare these findings with children who have similar complex cardiac conditions requiring surgery, but who do not have Alagille syndrome to see if bleeding conditions and complications are more or less common in children with Alagille syndrome.

Read the detailed description

This study aims to develop and implement a pre-operative screening protocol prior to major procedures or surgeries for children with Alagille syndrome, including cardiac catheterization and cardiothoracic surgery (pulmonary artery reconstruction).

Secondary Objectives

  1. Develop and implement an intra-operative protocol for children with Alagille syndrome and acquired von willebrand syndrome.
  2. Compare cardiac intra- and up to 48 hour post-operative bleeding complications, post-operative thrombotic complications within 30 days of surgery, and mortality for (a) children with Alagille syndrome with and without acquired von willebrand syndrome, and (b) children without Alagille syndrome.

This is a single-site study with the goal to enroll 40 patients over the course of the study period. All patients that are referred for Pulmonary Artery Reconstruction will be screened for eligibility. All patients will undergo standard of care pre-operative hematologic screening to evaluate for bleeding disorders (specifically platelet aggregation disorders and acquired von Willebrand Factor deficiency).

The study includes a pre-screening period of up to 4 weeks followed by a 12-months follow-up period as part of the standard of care following pulmonary artery reconstruction surgery for children with Alagille syndrome and a research related protocol for children without Alagille syndrome.

Patients would have blood drawn one time at least 2 weeks in advance of their cardiothoracic surgery. This is the screening protocol to understand if they have a bleeding disorder that would change their management in the operating room and after their surgery. For patients that are found to have a bleeding disorder requiring treatment, they would need post-operatively a blood test daily for up to 7 days total and another blood test weekly for 2 weeks and then once prior to discharge.

03

Conditions studied

  • Alagille Syndrome
  • Pulmonary Artery Stenoses
  • Acquired Von Willebrand Disease

Browse trials for

04

Who can participate

Ages eligible
Up to 17 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • 0-17 years old
  • with complex cardiac condition requiring pulmonary artery reconstruction (branch pulmonary artery stenosis, MAPCAs or Tetralogy of Fallot without MAPCAs)

Exclusion criteria

Exclusion Criteria:

  • history of known bleeding disorder
  • aged 18 years or older
05

Study design

Phase
Not applicable
Primary purpose
Prevention
Allocation
Non-randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
40 participants (estimated)

Study arms

  • Experimental
    Alagille syndrome

    Patients with complex cardiac conditions requiring cardiothoracic surgery who also have a history of Alagille syndrome.

    Other: Assessment for bleeding disorder with tailored post-operative care

  • Experimental
    No history of Alagille syndrome

    Patients with complex cardiac conditions requiring cardiothoracic surgery who do not have a diagnosis of Alagille syndrome.

    Other: Assessment for bleeding disorder with tailored post-operative care

Interventions

  • OtherAssessment for bleeding disorder with tailored post-operative care

    Intervention will be expanded lab work-up for hematologic conditions, consultation by Hematology and tailored intra-operative and post-operative plan with aim to mitigate bleeding and hemorrhage risk, balancing thrombotic risk with this intervention.

06

What researchers measure

Primary outcomes

  1. Blood product volume

    Time frame: Intra-operatively through 24 hours post-operatively

  2. Chest tube output blood volume

    Time frame: Intra-operatively through 24 hours post-operatively

  3. Number of participants with pulmonary hemorrhage

    Time frame: Intra-operatively through 24 hours post-operatively

Secondary outcomes

  1. Incidence of thromboembolism events in patients with hematologic condition

    This outcome is to evaluate thrombosis risk for patients identified to have a hematologic condition who receive medication intra-operatively and post-operatively to decrease their risk of bleeding. Occurrence of thromboembolism (including blood vessel, intracardiac, stroke, mediastinal thrombosis events) will be assessed based on imaging.

    Time frame: Intra-operatively through 30 days post-operatively

07

Study locations

1 site
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Apr 2023 (actual). Primary completion is estimated for Nov 2024, 19 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 26, 2023
First posted
May 6, 2023
StartActual
Apr 18, 2023
Primary completionEst.
Nov 2024
CompletionEst.
Nov 2024
Last update
May 6, 2023
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 6, 2023, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05846854
Collaborators
Alagille Syndrome Alliance
Responsible party
Noelle Hanako (Associate Professor, Division of Pediatric Gastroenterology, Hepatology and Nutrition, Stanford University) — Principal investigator
First posted
May 6, 2023
Start date
Apr 18, 2023
Primary completion
Nov 2024 (estimated)
Completion
Nov 2024 (estimated)
Last update
May 6, 2023

Study contacts

Noelle Ebel, MD
principal investigator · Stanford University

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

No contact was published for this record. The registry link below has the sponsor’s details.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion